Ignite Creation Date:
2024-07-17 @ 11:16 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481475
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-06-25
Brief Title:
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
Sponsor:
Chongqing Claruvis Pharmaceutical Co Ltd
Organization:
Chongqing Claruvis Pharmaceutical Co Ltd
Study Overview
Official Title:
A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection YY003 for the Treatment of Moderate to Severe Glabellar Lines in Adults
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a two-part Part A and Part B randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines The objective of this study is to test the safety efficacy immunogenicity of YY003 and compare to vehicel control in improving the appearance of moderate to severe glabellar lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None